Long intergenic non-protein coding RNA 1352 (LINC01352)

Long intergenic non-protein coding RNA 1352 (LINC01352) is a human long non-coding RNA gene that does not encode a protein but is transcribed as an RNA molecule[1]. As a member of the long intergenic non-coding RNA (lincRNA) family, LINC01352 is located outside of protein-coding gene regions and is implicated in regulating gene expression at various levels, including epigenetic, transcriptional, and post-transcriptional regulation[1]. There is evidence that LINC01352 expression can be suppressed by the hepatitis B virus X protein (HBx) in combination with estrogen receptor alpha (ERα), suggesting a possible role in hormone-related pathways and liver cancer circumstances[4]. There is currently no evidence that LINC01352 is a direct therapeutic target (e.g., receptor, enzyme, transporter) or that there are drugs that directly target it for therapy[1][4]. Its biological functions have been connected to the regulation of gene expression and potentially tumor suppression, but there is insufficient evidence to define it as a biomarker or clinical drug target at this time[1][4]. Summary of context: - LINC01352 is a long non-coding RNA (lncRNA), specifically a lincRNA, not coding for protein[1]. - Its main biological function is thought to be in regulation of gene expression and possibly tumor suppression, particularly influenced by viral and hormonal pathways[4]. - Disease association is noted in cancer, with some evidence for functional relevance in liver cancer and possible roles in other malignancies[1][4]. - It is not a canonical therapeutic target; there are no drugs or mechanism-of-action annotations related to therapies[1][4]. - No specific biomarker or safety concern information is available. If more detailed functional roles in specific cancers or evidence of relevance as a biomarker emerge, these could be incorporated in structured records in future updates.

Other names

LINC01352